{
  "video_id": "x9IjYFt98wQ",
  "title": "Duration of Chemotherapy and Neurotoxicity",
  "es": 0,
  "json": [
    {
      "index": 1,
      "start_time": 5880.0,
      "end_time": 12360.0,
      "text": "Six months of oxaliplatin-based chemotherapy is the standard adjuvant therapy in stage III colon cancer."
    },
    {
      "index": 2,
      "start_time": 12360.0,
      "end_time": 17780.0,
      "text": "Sensory-based neurotoxicity is a troublesome dose-limiting adverse effect of oxaliplatin"
    },
    {
      "index": 3,
      "start_time": 17780.0,
      "end_time": 20800.0,
      "text": "that can affect a patientâ€™s quality of life."
    },
    {
      "index": 4,
      "start_time": 20800.0,
      "end_time": 24180.0,
      "text": "Since the neurotoxicity of oxaliplatin depends on the cumulative dose,"
    },
    {
      "index": 5,
      "start_time": 24180.0,
      "end_time": 29480.0,
      "text": "could shorter adjuvant therapy be beneficial for patients if efficacy could be maintained?"
    },
    {
      "index": 6,
      "start_time": 29480.0,
      "end_time": 37500.0,
      "text": "This pooled analysis of concurrent randomized phase 3 trials evaluated noninferiority in 12,834 patients"
    },
    {
      "index": 7,
      "start_time": 37500.0,
      "end_time": 44560.0,
      "text": "randomized to three or six months of FOLFOX, a combination of oxaliplatin, fluorouracil, and leucovorin,"
    },
    {
      "index": 8,
      "start_time": 44560.0,
      "end_time": 48960.0,
      "text": "or CAPOX, a combination of oxaliplatin and capecitabine."
    },
    {
      "index": 9,
      "start_time": 48960.0,
      "end_time": 52980.0,
      "text": "In the overall study population, noninferiority was not confirmed,"
    },
    {
      "index": 10,
      "start_time": 52980.0,
      "end_time": 59879.0,
      "text": "with a 3-year disease-free survival rate of 74.6% in patients randomized to 3 months of treatment"
    },
    {
      "index": 11,
      "start_time": 59880.0,
      "end_time": 63980.0,
      "text": "and 75.5% in patients randomized to 6 months."
    },
    {
      "index": 12,
      "start_time": 63980.0,
      "end_time": 68119.0,
      "text": "The noninferiority of 3 versus 6 months was seen for CAPOX,"
    },
    {
      "index": 13,
      "start_time": 68120.0,
      "end_time": 71600.0,
      "text": "but 3 months of FOLFOX was inferior to 6 months."
    },
    {
      "index": 14,
      "start_time": 71600.0,
      "end_time": 77609.0,
      "text": "In exploratory subgroup analyses of combined regimens, 3 months was noninferior to 6 months"
    },
    {
      "index": 15,
      "start_time": 77609.0,
      "end_time": 85539.0,
      "text": "for T1 to 3N1 disease, and 6 months was superior to 3 months for T4 and N2 cancers."
    },
    {
      "index": 16,
      "start_time": 85540.0,
      "end_time": 90520.0,
      "text": "The authors conclude that noninferiority was not confirmed for the overall study population,"
    },
    {
      "index": 17,
      "start_time": 90520.0,
      "end_time": 95600.0,
      "text": "but that disease-free survival was strongly affected by treatment regimen and risk group."
    },
    {
      "index": 18,
      "start_time": 95600.0,
      "end_time": 98500.0,
      "text": "Full trial results at NEJM.org"
    }
  ]
}